Anne M. Traynor

4.1k total citations
117 papers, 2.9k citations indexed

About

Anne M. Traynor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anne M. Traynor has authored 117 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Anne M. Traynor's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (19 papers) and Cancer therapeutics and mechanisms (13 papers). Anne M. Traynor is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (19 papers) and Cancer therapeutics and mechanisms (13 papers). Anne M. Traynor collaborates with scholars based in United States, Singapore and France. Anne M. Traynor's co-authors include Joan H. Schiller, Jill Kolesar, Jens C. Eickhoff, George Wilding, Deepak Khuntia, Charles Erlichman, William J. Maples, Sarita Dubey, Jill M. Siegfried and Tien Hoang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anne M. Traynor

113 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne M. Traynor United States 32 1.3k 1.1k 933 390 293 117 2.9k
Tracey L. Evans United States 29 2.1k 1.6× 2.1k 1.8× 933 1.0× 194 0.5× 583 2.0× 107 4.0k
Alicia K. Morgans United States 29 1.1k 0.8× 1.9k 1.6× 557 0.6× 261 0.7× 429 1.5× 202 3.4k
Aurelius Omlin Switzerland 32 1.3k 1.0× 1.9k 1.6× 816 0.9× 210 0.5× 985 3.4× 115 3.6k
Pepijn Brocken Netherlands 6 1.3k 0.9× 1.2k 1.1× 946 1.0× 79 0.2× 589 2.0× 8 3.1k
Susan Dent United States 34 2.1k 1.5× 945 0.8× 658 0.7× 116 0.3× 546 1.9× 138 4.3k
Adolfo Favaretto Italy 31 1.7k 1.3× 2.2k 1.9× 780 0.8× 119 0.3× 357 1.2× 136 3.7k
Steven Waggoner United States 38 1.8k 1.4× 581 0.5× 1.0k 1.1× 71 0.2× 545 1.9× 136 5.0k
Roman Gulati United States 34 1.6k 1.2× 2.3k 2.0× 672 0.7× 179 0.5× 662 2.3× 128 3.6k
Hiroji Uemura Japan 31 804 0.6× 2.5k 2.2× 1.0k 1.1× 675 1.7× 809 2.8× 165 4.1k
Paolo Carlini Italy 34 1.7k 1.3× 1.0k 0.9× 630 0.7× 65 0.2× 774 2.6× 125 3.2k

Countries citing papers authored by Anne M. Traynor

Since Specialization
Citations

This map shows the geographic impact of Anne M. Traynor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne M. Traynor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne M. Traynor more than expected).

Fields of papers citing papers by Anne M. Traynor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne M. Traynor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne M. Traynor. The network helps show where Anne M. Traynor may publish in the future.

Co-authorship network of co-authors of Anne M. Traynor

This figure shows the co-authorship network connecting the top 25 collaborators of Anne M. Traynor. A scholar is included among the top collaborators of Anne M. Traynor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne M. Traynor. Anne M. Traynor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colgan, Timothy J., Daiki Tamada, Toby C. Campbell, et al.. (2024). Uncorrected and subcutaneous fat‐corrected echo intensities are similarly associated with magnetic resonance imaging per cent fat. SHILAP Revista de lepidopterología. 7(1). 66–75.
2.
Juloori, Aditya, Gregory N. Gan, Jun Zhang, et al.. (2023). Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS8615–TPS8615. 1 indexed citations
3.
He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations
4.
5.
Linehan, W. Marston, Viola W. Zhu, Adam J. Schoenfeld, et al.. (2018). Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology. 13(10). 1530–1538. 54 indexed citations
6.
Chang, Elizabeth, Lakeesha Carmichael, KyungMann Kim, et al.. (2017). VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma & Leukemia. 18(1). e61–e67. 11 indexed citations
7.
Traynor, Anne M., Toby C. Campbell, Kari B. Wisinski, et al.. (2017). Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. Journal of Oncology Pharmacy Practice. 24(5). 348–353. 6 indexed citations
8.
Schehr, Jennifer L., Jay W. Warrick, David J. Guckenberger, et al.. (2016). High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. PLoS ONE. 11(7). e0159397–e0159397. 55 indexed citations
9.
Nyflot, Matthew J., Tim J. Kruser, Anne M. Traynor, et al.. (2015). Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology*Biology*Physics. 91(5). 942–951. 33 indexed citations
10.
Rajguru, Saurabh, et al.. (2014). Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.. PubMed. 12(8). 509–15. 6 indexed citations
11.
Traynor, Anne M., Tracey L. Weigel, Kurt R. Oettel, et al.. (2013). Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 81(1). 138–141. 57 indexed citations
12.
Hall, Lance T., et al.. (2013). Relative biodistribution and tumor uptake of 124I-CLR1404 (aka NM404) in non-small cell lung cancer (NSCLC) patients. 54(4). 278–278. 1 indexed citations
13.
Campbell, Toby C., Tien Hoang, Songwon Seo, et al.. (2011). Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(5). 951–953. 9 indexed citations
14.
Traynor, Anne M., Glenn Liu, Keith T. Flaherty, et al.. (2010). Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(2). 305–314. 73 indexed citations
15.
Sankhala, Kamalesh K., E. Gabriela Chiorean, Andrew J. Armstrong, et al.. (2010). Phase I/II study of TH-302 in combination with docetaxel in patients with solid tumors including NSCLC and castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 28(15_suppl). e13527–e13527. 3 indexed citations
16.
Robert, Francisco, Alan Sandler, Joan H. Schiller, et al.. (2009). Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology. 66(4). 669–680. 32 indexed citations
17.
Attia, Steven, Kyle D. Holen, Howard H. Bailey, et al.. (2008). Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64(1). 45–51. 4 indexed citations
18.
Tomé, Wolfgang A., H. Jaradat, Nigel P. Orton, et al.. (2006). Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncologica. 45(7). 890–896. 64 indexed citations
19.
Traynor, Anne M. & Joan H. Schiller. (2004). Systemic treatment of advanced non-small cell lung cancer. Drugs of today. 40(8). 697–697. 16 indexed citations
20.
Gazitt, Yair, G. David Roodman, César O. Freytes, et al.. (2000). A phase I-II clinical trial with a combination of gemcitabine (GEMZAR) and paclitaxel (TAXOL) for the treatment of refractory multiple myeloma (MM) patients. Blood. 96. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tracey L. Evans Breakdown of academic impact, for papers by Alicia K. Morgans Breakdown of academic impact, for papers by Aurelius Omlin Breakdown of academic impact, for papers by Pepijn Brocken Breakdown of academic impact, for papers by Susan Dent Breakdown of academic impact, for papers by Adolfo Favaretto Breakdown of academic impact, for papers by Steven Waggoner Breakdown of academic impact, for papers by Roman Gulati Breakdown of academic impact, for papers by Hiroji Uemura Breakdown of academic impact, for papers by Paolo Carlini
Rankless by CCL
2026